Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 4, 2001, Pages 425-427

  Tan, Adriaan C I T L ^a   Kruimel, Johanna W ^a   Naber, Ton H J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Budesonide; Corticosteroids; Eosinophilic gastroenteritis; Keywords; Treatment

Indexed keywords

BUDESONIDE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIC GASTROENTERITIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SIDE EFFECT; STOMACH BIOPSY; TABLET FORMULATION;

ADULT; BUDESONIDE; EOSINOPHILIA; FEMALE; GASTROENTERITIS; GLUCOCORTICOIDS; HUMANS;

EID: 0035053849     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200104000-00021     Document Type: Article

References (12)

1. Talley NT, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 1990; 31: 54 -58.
2. Steffen RM, Wyllie R, Petras RE, Caulfield ME, Michener WM, Firor HV. et al. The spectrum of eosinophilic gastroenteritis. Report of six pediatric cases and review of the literature. Clin Pediatr (Phila) 1991; 30: 404 -411.
3. Jaffe JS, James SP, Mullings GE, Braun-Elwert L, Lubensky I, Metcalfe DD. Evidence for an abnormal profile of interleukin-4 (IL-4), IL-5 and gamma-interferon (gamma-IFN) in peripheral blood T cells from patients with allergic eosinophilic gastroenteritis. J Clin Immunol 1994; 14: 299 -309.
4. Keshavarzian A, Saverymuttu SH, Tai PC, Thompson M, Barter S, Spry CJ. et al. Activated eosinophils in familial eosinophilic gastroenteritis. Gastroenterology 1985; 88: 1041 -1049.
5. Torpier G, Colombel JF, Mathieu-Chandelier C, Capron M, Dessaint JP, Cortot A. et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophilic major basic protein. Clin Exp Immunol 1988; 74: 404 -408.
6. Beil WJ, Weller PF, Tzizik DM, Galli SJ, Dvorak AM. Ultrastructural immunogold localization of tumor necrosis factor-alpha to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem 1993; 41: 1611 -1615.
7. Lee CM, Changchien CS, Chen PC, Lin DY, Sheen IS, Wang CS. et al. Eosinophilic gastroenteritis: 10 years experience. Am J Gastroenterol 1993; 88: 70 -74.
8. Di Gioacchino M, Pizzicannella G, Fini N, Falasca F, Antinucci R, Masci S. et al. Sodium dicromoglycate in the treatment of eosinophilic gastroenteritis. Allergy 1990; 45: 161 -166.
9. Hamedani R, Feldman RD, Feagan BG. Review article: drug development in inflammatory bowel disease: budesonide - a model of targeted therapy. Aliment Pharmacol Ther 1997; 11: 98 -107.
10. Thomsen O, Cortot A, Jewell D. et al. Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week, international randomised, double-blind multicentre trial. N Engl J Med 1999; 339: 370 -374.
11. Russel MGVM, Zeijen RNM, Brummer RJM, de Bruine AP, van Kroonenburgh MJPG, Stockbrugger RW. Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR). Gut 1994; 35: 1490 -1492.
12. Wikberg M, Ulmius J, Ragnarsson G. Review article: targeted drug delivery in treatment of intestinal diseases. Aliment Pharmacol Ther 1997; 11 (suppl 3): 109 -115.